Major Shareholder Announcement
July 21, 2021 12:58 ET
|
Genmab A/S
Company Announcement Major shareholder announcement for Genmab A/S Copenhagen, Denmark; July 21, 2021 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital...
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Second Quarter of 2021
July 21, 2021 06:31 ET
|
Genmab A/S
Company Announcement Net sales of DARZALEX® in the second quarter of 2021 totaled USD 1,433 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. Copenhagen, Denmark;...
Capital Increase in Genmab as a Result of Employee Warrant Exercise
July 06, 2021 14:04 ET
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; July 06, 2021 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 47,974 shares as a consequence of the exercise of employee warrants. The...
Completion of share buy-back program
July 01, 2021 03:42 ET
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; July 01, 2021 – Genmab A/S (Nasdaq: GMAB) announces that its share buy-back program has been completed on June 30, 2021. On February 23, 2021 Genmab...
Transactions in connection with share buy-back program
June 28, 2021 03:30 ET
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; June 28, 2021 – Genmab A/S (Nasdaq: GMAB). On February 23, 2021 Genmab announced the initiation of a share buy-back program to mitigate dilution from warrant...
Grant of Restricted Stock Units and Warrants to Employees in Genmab
June 22, 2021 16:16 ET
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; June 22, 2021 – Genmab A/S (Nasdaq: GMAB) announced today that at a board meeting the board decided to grant 15,241 restricted stock units and 16,335...
Genmab Announces that Janssen has Received European Marketing Authorizations for DARZALEX® (daratumumab) Subcutaneous Formulation, Including for the Treatment of Patients with Newly Diagnosed Light-chain (AL) Amyloidosis
June 22, 2021 10:12 ET
|
Genmab A/S
Company Announcement Janssen received European approval for DARZALEX® SC (daratumumab and hyaluronidase-fihj) in combination with bortezomib, cyclophosphamide and dexamethasone for the treatment of...
Transactions in connection with share buy-back program
June 21, 2021 03:46 ET
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; June 21, 2021 – Genmab A/S (Nasdaq: GMAB). On February 23, 2021 Genmab announced the initiation of a share buy-back program to mitigate dilution from warrant...
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
June 15, 2021 19:12 ET
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; June 16, 2021 – Genmab A/S (Nasdaq: GMAB) In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523,...
Transactions in connection with share buy-back program
June 14, 2021 03:57 ET
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; June 14, 2021 – Genmab A/S (Nasdaq: GMAB). On February 23, 2021 Genmab announced the initiation of a share buy-back program to mitigate dilution from warrant...